Breakdown | ||||
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.36M | 50.90K | 78.13K | 7.85M | 443.55K | Gross Profit |
937.48K | -505.24K | -558.01K | 7.06M | 87.74K | EBIT |
0.00 | -767.60K | -1.20M | 5.27M | -390.42K | EBITDA |
-811.88K | -788.22K | -695.49K | 5.28M | -371.80K | Net Income Common Stockholders |
-7.25M | 1.58M | 1.45M | 13.94M | -575.53K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.74M | 934.86K | 1.89M | 2.14M | 684.89K | Total Assets |
3.50M | 11.61M | 7.06M | 3.20M | 2.08M | Total Debt |
0.00 | 0.00 | 0.00 | 13.18K | 22.02K | Net Debt |
-1.74M | -934.86K | -1.89M | -2.13M | -662.88K | Total Liabilities |
104.14K | 1.09M | 449.86K | 632.92K | 302.70K | Stockholders Equity |
3.40M | 10.52M | 6.63M | 2.57M | 1.70M |
Cash Flow | Free Cash Flow | |||
-736.12K | -768.19K | -1.28M | -1.29M | -369.20K | Operating Cash Flow |
-736.12K | -768.19K | -1.27M | -1.28M | -352.20K | Investing Cash Flow |
1.54M | -1.08M | -1.40M | 17.09M | -34.78K | Financing Cash Flow |
0.00 | 930.36K | 2.42M | -14.35M | -135.41K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | 4.41 | 21.58% | ― | 52.96% | 30.01% | ||
73 Outperform | 22.59 | 3.22% | 7.17% | -3.67% | 51.49% | ||
66 Neutral | 7.42 | 12.49% | 0.44% | ― | ― | ||
64 Neutral | $12.82B | 9.83 | 7.68% | 17000.34% | 12.38% | -5.56% | |
52 Neutral | £561.90M | ― | -0.51% | ― | 59.93% | 97.07% | |
43 Neutral | £1.43M | ― | -97.45% | ― | 502.47% | -501.58% |
Braveheart Investment Group plc has increased its stake in IQ-AI Ltd by subscribing to 7,000,000 new shares in a recent placing, raising its holding to 29.35% of IQ-AI’s enlarged share capital. This strategic investment is seen as a significant addition to Braveheart’s portfolio, potentially enhancing its market position and offering stakeholders increased value through IQ-AI’s innovative imaging platforms and therapeutics.